

Q1 2022 Financial Results

Appendix

Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended	
	March 31, 2022	March 31, 2021
Reconciliation of GAAP to Non-GAAP research and development:		
GAAP Research and development	\$ 169,893	\$ 185,899
Less: Stock-based compensation expenses	(11,617)	(24,375)
Non-GAAP Research and development	<u>\$ 158,276</u>	<u>\$ 161,524</u>
Reconciliation of GAAP to Non-GAAP selling, general and administrative:		
GAAP Selling, general and administrative	\$ 154,471	\$ 146,859
Less: Stock-based compensation expenses	(17,676)	(31,315)
Non-GAAP Selling, general and administrative	<u>\$ 136,795</u>	<u>\$ 115,544</u>
Reconciliation of GAAP to Non-GAAP operating loss:		
GAAP operating loss	\$ (146,732)	\$ (186,254)
Add: Stock-based compensation expenses	29,293	55,690
Non-GAAP operating loss	<u>\$ (117,439)</u>	<u>\$ (130,564)</u>

Anylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Operating Expense Growth at Constant Currency

	Three Months Ended March 31, 2022
Net product revenues as reported	38 %
Less: Impact of foreign currency translation	5
Net product revenues growth at constant currency	<u>43 %</u>
Total revenues as reported	20 %
Less: Impact of foreign currency translation	4
Total revenues growth at constant currency	<u>24 %</u>
Non-GAAP Research and development as reported	(2)%
Less: Impact of foreign currency translation	1
Non-GAAP research and development at constant currency	<u>(1)%</u>
Non-GAAP Selling, general and administrative as reported	18 %
Less: Impact of foreign currency translation	2
Non-GAAP selling, general and administrative at constant currency	<u>20 %</u>
Non-GAAP operating loss as reported	(10)%
Less: Impact of foreign currency translation	(5)
Non-GAAP operating loss at constant currency	<u>(15)%</u>